Full-Time
Posted on 9/15/2025
FDA-approved neurostimulation device for OSA
$170k - $230k/yr
Minneapolis, MN, USA
In Person
| , , , , , , |
Inspire Medical Systems develops and sells a minimally invasive implantable device for obstructive sleep apnea (OSA). Its lead product, the Inspire system, uses implanted neurostimulation to activate the hypoglossal nerve, which moves the tongue and other airway muscles to keep the airway open during sleep. Patients control the therapy with a small handheld remote. The system targets adults with moderate to severe OSA who cannot use or benefit consistently from CPAP. Unlike non-implant options, Inspire provides a hands-free, on-demand airway support during sleep and is the first FDA-approved neurostimulation treatment for OSA. The company differentiates itself by offering a clinically approved implantable alternative to CPAP, backed by a direct US sales force and a network in Europe. Its goal is to provide an effective, durable option for patients who struggle with CPAP, expanding access to neurostimulation therapy to improve sleep quality and health outcomes.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Golden Valley, Minnesota
Founded
2007
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Tuition Reimbursement
Employee Assistance program
Employee Stock Purchase Plan
Swindon hospital to offer device to help with sleep apnoea. Great Western Hospital will receive access to specialist sleep apnoea technology. (Image: Dave Cox) Swindon's hospital will be one of a select few health hubs in the UK to receive a high-tech medical device which will help patients. Great Western Hospital is one of 12 centres now offering access to Inspire, a surgically implanted device for the treatment of moderate-to-severe obstructive sleep apnoea in patients who cannot tolerate CPAP therapy. Developed by Inspire Medical Systems, the implant works by stimulating the hypoglossal nerve to keep the airway open during sleep. The device is about the size of two 50p coins and is activated each night with a handheld remote. Patients turn it on before going to sleep and then switch it off upon waking up. Recommended reading Ed Holyoak from Inspire said: "Inspire has expanded its footprint significantly in Europe with over 80 employees to support the implementation of the therapy and the growing NHS adoption in England. "Thisiswiltshire is experiencing strong year-on-year growth, expanding European presence, and accelerating adoption across key European health systems. "We are very proud to bring the benefits of our sleep solution to the UK." It will also be provided to hospitals in London, Nottingham, Leeds, and Birmingham. Inspire therapy was introduced to the NHS in 2023, with the first patients treated at Guy's and St Thomas' Hospital in London. Clinical data has shown that 91 percent of patients are satisfied with the device, and 92 percent would choose it again. Roughly 94 percent would recommend it to family or friends. Bed partner surveys found that 90 percent reported no or only soft snoring. The system is not suitable for everyone and requires specialist assessment. It is intended for adults with moderate-to-severe OSA who do not respond to, or cannot use, CPAP therapy. Possible risks include infection and temporary tongue weakness, with rare cases of tongue paresis or atrophy. Some patients may require post-implant adjustments to improve comfort and effectiveness. The expansion of Inspire therapy in the UK is supported by increasing clinical adoption, physician training, and partnerships with national sleep organisations such as The Sleep Charity. Support from the NHS and patient education efforts have contributed to growing awareness and demand. Inspire Medical Systems was founded by Tim Herbert in the US. The device received FDA approval in 2014 and has held a CE mark in Europe since 2010. Obstructive sleep apnoea affects approximately 25 percent of the UK population. If left untreated, it can raise the risk of type 2 diabetes, stroke, heart attack, depression, and shortened life expectancy.
Inspire Medical Systems reported strong fourth-quarter 2025 results, with revenue rising 12.2% year on year. The company issued its highest full-year guidance raise amongst peers, supported by early commercial feedback on its next-generation Inspire V neurostimulator. The investment story is being reshaped by new Centers for Medicare & Medicaid Services procedure codes for hypoglossal nerve stimulation, which directly affect how centres bill for Inspire's procedures. These codes influence near-term access, implanter economics and the pace of Inspire V adoption. The company completed enrolment in its PREDICTOR study. Despite strong quarterly performance, the new Medicare coding framework and mixed analyst reactions keep reimbursement risk central to the investment case. Inspire Medical Systems' narrative projects $1.3 billion revenue and $103.6 million earnings by 2028.
Inspire Medical Systems reported fourth-quarter revenues of $269.1 million, up 12.2% year-on-year and exceeding analyst expectations by 1.1%. The company, which develops implantable neurostimulation devices for treating obstructive sleep apnea, also beat earnings per share estimates and full-year EPS guidance. The medical devices and supplies specialty sector showed mixed results in Q4, with the seven tracked stocks missing revenue consensus estimates by 2.1% on average. Share prices declined 1.2% on average following the latest earnings results. CEO Tim Herbert highlighted progress with the Inspire V launch, noting that early commercial adoption has validated positive patient outcomes and improvements in therapy delivery. The device offers an alternative to traditional CPAP machines for sleep apnea treatment.
Wells Fargo has lowered its price target on Inspire Medical Systems to $145 from $160 whilst maintaining an Overweight rating, citing potential short-term reimbursement concerns. The firm remains confident the company will resolve these issues, with clarity expected during its fourth-quarter earnings call. The Minnesota-based medical technology company, which develops neurostimulation solutions for obstructive sleep apnea patients, reported strong preliminary results on 12 January. It projects 2026 revenue of $1.003–$1.013 billion and fourth-quarter revenue of $268.9–$269.1 million, both exceeding consensus expectations. Inspire Medical's flagship system provides an alternative for patients who cannot tolerate CPAP therapy, using minimally invasive neurostimulation to improve airway function and quality of life.
Bleichmar Fonti & Auld files class action against Inspire Medical Systems for securities fraud. Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Inspire Medical Systems and senior executives for securities fraud. The lawsuit alleges violations of federal securities laws, leading to a significant stock drop. Investors who invested in Inspire are encouraged to visit https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit for additional information. The case is pending in the U.S. District Court for the District of Minnesota. Investors have until January 5, 2026, to ask the Court to lead the case. Ask Aime: Is Now the Time to Buy or Sell Inspire Medical Systems Stock Amidst Legal Turmoil? Or continue with others.